Aptamers against extracellular targets for in vivo applications

Biochimie

Volumn 87, Issue 9-10, 2005, Pages 921-930

  Pestourie, C ^a   Tavitian, B ^a   Duconge, F ^a  

^a DIF   (France)

Author keywords

Aptamers; Diagnostic; In vivo; SELEX; Therapeutic

Indexed keywords

ANTIBIOTIC AGENT; APTAMER; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; CELL MARKER; GROWTH FACTOR; HORMONE; NEUROPEPTIDE; NUCLEASE; OLIGONUCLEOTIDE; PEPTIDE; RECEPTOR PROTEIN;

AMINO ACID SEQUENCE; AUTOIMMUNE DISEASE; CIRCULATION; CONFERENCE PAPER; CONFORMATION; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOGENICITY; INFECTION; INFLAMMATION; MOLECULAR IMAGING; NEUROPATHOLOGY; NONHUMAN; PHENOTYPE; PROTEIN BINDING; PROTEIN PURIFICATION; RETINA MACULA DEGENERATION;

AUTOIMMUNE DISEASES; BASE SEQUENCE; GENE LIBRARY; HUMANS; OLIGONUCLEOTIDES; THROMBIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 24744466474     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2005.04.013     Document Type: Conference Paper

References (109)

1. T.R. Cech RNA finds a simpler way Nature 428 2004 263 264
2. D.L. Robertson, and G.F. Joyce Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA Nature 344 1990 467 468
3. R. Green, A.D. Ellington, and J.W. Szostak In vitro genetic analysis of the tetrahymena self-splicing intron Nature 347 1990 406 408
4. H.J. Thiesen, and C. Bach Target Detection Assay (TDA): a versatile procedure to determine DNA binding sites as demonstrated on SP1 protein Nucleic Acids Res. 18 1990 3203 3209
5. T.K. Blackwell, L. Kretzner, E.M. Blackwood, R.N. Eisenman, and H. Weintraub Sequence-specific DNA binding by the c-Myc protein Science 250 1990 1149 1151
6. T.K. Blackwell, and H. Weintraub Differences and similarities in DNA-binding preferences of MyoD and E2A protein complexes revealed by binding site selection Science 250 1990 1104 1110
7. R. Pollock, and R. Treisman A sensitive method for the determination of protein-DNA binding specificities Nucleic Acids Res. 18 1990 6197 6204
8. A.D. Ellington, and J.W. Szostak In vitro selection of RNA molecules that bind specific ligands Nature 346 1990 818 822
9. C. Tuerk, and L. Gold Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase Science 249 1990 505 510
10. S.E. Osborne, I. Matsumura, and A.D. Ellington Aptamers as therapeutic and diagnostic reagents: problems and prospects Curr. Opin. Chem. Biol. 1 1997 5 9
11. L. Gold, B. Polisky, O. Uhlenbeck, and M. Yarus Diversity of oligonucleotide functions Annu. Rev. Biochem. 64 1995 763 797
12. T. Fitzwater, and B. Polisky A SELEX primer Methods Enzymol. 267 1996 275 301
13. R.C. Conrad, S. Baskerville, and A.D. Ellington In vitro selection methodologies to probe RNA function and structure Mol. Divers. 1 1995 69 78
14. T. Hermann, and D.J. Patel Adaptive recognition by nucleic acid aptamers Science 287 2000 820 825
15. R.R. Breaker DNA aptamers and DNA enzymes Curr. Opin. Chem. Biol. 1 1997 26 31
16. P.K.R. Kumar, and A.D. Ellington Artificial evolution and natural ribozymes FASEB J. 9 1995 1183 1195
17. G. Joyce RNA evolution and the origin of life Nature 338 1989 217 224
18. M. Rimmele Nucleic acid aptamers as tools and drugs: recent developments ChemBioChem. 4 2003 963 971
19. P. Burgstaller, A. Girod, and M. Blind Aptamers as tools for target prioritization and lead identification Drug Discov. Today 7 2002 1221 1228
20. L. Cerchia, J. Hamm, D. Libri, B. Tavitian, and V. De Franciscis Nucleic acid aptamers in cancer medicine FEBS Lett. 528 2002 12 16
21. J. Hesselberth, M.P. Robertson, S. Jhaveri, and A.D. Ellington In vitro selection of nucleic acids for diagnostic applications J. Biotechnol. 74 2000 15 25
22. E.N. Brody, and L. Gold Aptamers as therapeutic and diagnostic agents J. Biotechnol. 74 2000 5 13
23. R.K. Jain The next frontier of molecular medicine: delivery of therapeutics Nat. Med. 4 1998 655 657
24. G.P. Dietz, and M. Bahr Delivery of bioactive molecules into the cell: the Trojan horse approach Mol. Cell. Neurosci. 27 2004 85 131
25. R.E. Martell, J.R. Nevins, and B.A. Sullenger Optimizing aptamer activity for gene therapy applications using expression cassette SELEX Mol. Ther. 6 2002 30 34
26. M. Famulok, G. Mayer, and M. Blind Nucleic acid aptamers - from selection in vitro to applications in vivo Acc. Chem. Res. 33 2000 591 599
27. L.C. Bock, L.C. Griffin, J.A. Latham, E.H. Vermaas, and J.J. Toole Selection of single-stranded DNA molecules that bind and inhibit human thrombin Nature 355 1992 564 566
28. J.A. Kelly, J. Feigon, and T.O. Yeates Reconciliation of the X-ray and NMR structures of the thrombin-binding aptamer d(GGTTGGTGTGGTTGG) J. Mol. Biol. 256 1996 417 422
29. L.C. Griffin, G.F. Tidmarsh, L.C. Bock, J.J. Toole, and L.L. Leung In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits Blood 81 1993 3271 3276
30. S.T. Crooke, and C.F. Bennett Progress in antisense oligonucleotide therapeutic Annu. Rev. Pharmacol. Toxicol. 36 1996 107 129
31. J. Micklefield Backbone modification of nucleic acids: synthesis, structure and therapeutic applications Curr. Med. Chem. 8 2001 1157 1179
32. R. Padilla, and R. Sousa Efficient synthesis of nucleic acids heavily modified with non-canonical ribose 2′-groups using a mutantT7 RNA polymerase (RNAP) Nucleic Acids Res. 27 1999 1561 1563
33. C.P. Rusconi, E. Scardino, J. Layzer, G.A. Pitoc, T.L. Ortel, and D. Monroe RNA aptamers as reversible antagonists of coagulation factor IXa Nature 419 2002 90 94
34. C.P. Rusconi, J.D. Roberts, G.A. Pitoc, S.M. Nimjee, R.R. White, and G. Quick Antidote-mediated control of an anticoagulant aptamer in vivo Nat. Biotechnol. 22 2004 1423 1428
35. J. Featherstone, and S. Griffiths From the analyst's couch. Drugs that target angiogenesis Nat. Rev. Drug Discov. 1 2002 413 414
36. J. Ruckman, L.S. Green, J. Beeson, S. Waugh, W.L. Gillette, and D.D. Henninger 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain J. Biol. Chem. 273 1998 20556 20567
37. www.macugen.com.
38. T. Ostendorf, U. Kunter, F. Eitner, A. Loos, H. Regele, and D. Kerjaschki VEGF(165) mediates glomerular endothelial repair J. Clin. Invest. 104 1999 913 923
39. J. Huang, J. Moore, S. Soffer, E. Kim, D. Rowe, and C.A. Manley Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors J. Pediatr. Surg. 36 2001 357 361
40. E.S. Kim, A. Serur, J. Huang, C.A. Manley, K.W. McCrudden, and J.S. Frischer Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma Proc. Natl. Acad. Sci. USA 99 2002 11399 11404
41. J. Floege, T. Ostendorf, U. Janssen, M. Burg, H.H. Radeke, and C. Vargeese Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers Am. J. Pathol. 154 1999 169 179
42. O. Leppanen, N. Janjic, M.A. Carlsson, K. Pietras, M. Levin, and C. Vargeese Intimal hyperplasia recurs after removal of PDGF-AB and -BB inhibition in the rat carotid artery injury model Arterioscler. Thromb. Vasc. Biol. 20 2000 E89 E95
43. K. Pietras, A. Ostman, M. Sjoquist, E. Buchdunger, R.K. Reed, and C.H. Heldin Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors Cancer Res. 61 2001 2929 2934
44. K. Pietras, K. Rubin, T. Sjoblom, E. Buchdunger, M. Sjoquist, and C.H. Heldin Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy Cancer Res. 62 2002 5476 5484
45. S. Klussmann, A. Nolte, R. Bald, V.A. Erdmann, and J.P. Furste Mirror-image RNA that binds d-adenosine Nat. Biotechnol. 14 1996 1112 1115
46. A. Nolte, S. Klussmann, R. Bald, V.A. Erdmann, and J.P. Furste Mirror-design of l-oligonucleotide ligands binding to l-arginine Nat. Biotechnol. 14 1996 1116 1119
47. B. Wlotzka, S. Leva, B. Eschgfaller, J. Burmeister, F. Kleinjung, and C. Kaduk In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class Proc. Natl. Acad. Sci. USA 99 2002 8898 8902
48. S. Helmling, C. Maasch, D. Eulberg, K. Buchner, W. Schroder, and C. Lange Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer Proc. Natl. Acad. Sci. USA 101 2004 13174 13179
49. Y.M. Kim, K.H. Choi, Y.J. Jang, J. Yu, and S. Jeong Specific modulation of the anti-DNA autoantibody-nucleic acids interaction by the high affinity RNA aptamer Biochem. Biophys. Res. Commun. 300 2003 516 523
50. B. Hwang, K. Han, and S.W. Lee Prevention of passively transferred experimental autoimmune myasthenia gravis by an in vitro selected RNA aptamer FEBS Lett. 548 2003 85 89
51. B. Hwang, and S.W. Lee Improvement of RNA aptamer activity against myasthenic autoantibodies by extended sequence selection Biochem. Biophys. Res. Commun. 290 2002 656 662
52. Y. Lin, Q. Qiu, S.C. Gill, and S.D. Jayasena Modified RNA sequence pools for in vitro selection Nucleic Acids Res. 22 1994 5229 5234
53. Y. Lin, A. Padmapriya, K.M. Morden, and S.D. Jayasena Peptide conjugation to an in vitro-selected DNA ligand improves enzyme inhibition Proc. Natl. Acad. Sci. USA 92 1995 11044 11048
54. J. Charlton, G.P. Kirschenheuter, and D. Smith Highly potent irreversible inhibitors of neutrophil elastase generated by selection from a randomized DNA-valine phosphonate library Biochemistry 36 1997 3018 3026
55. N.M. Bless, D. Smith, J. Charlton, B.J. Czermak, H. Schmal, and H.P. Friedl Protective effects of an aptamer inhibitor of neutrophil elastase in lung inflammatory injury Curr. Biol. 7 1997 877 880
56. B.J. Hicke, S.R. Watson, A. Koenig, C.K. Lynott, R.F. Bargatze, and Y.F. Chang DNA aptamers block l-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice J. Clin. Invest. 98 1996 2688 2692
57. S.R. Watson, Y.F. Chang, D. O'Connell, L. Weigand, S. Ringquist, and D.H. Parma Anti-l-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo Antisense Nucleic Acid Drug Dev. 10 2000 63 75
58. F. Ylera, R. Lurz, V.A. Erdmann, and J.P. Furste Selection of RNA aptamers to the Alzheimer's disease amyloid peptide Biochem. Biophys. Res. Commun. 290 2002 1583 1588
59. S. Weiss, D. Proske, M. Neumann, M.H. Groschup, H.A. Kretzschmar, and M. Famulok RNA aptamers specifically interact with the prion protein PrP J. Virol. 71 1997 8790 8797
60. A. Rhie, L. Kirby, N. Sayer, R. Wellesley, P. Disterer, and I. Sylvester Characterization of 2′-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion J. Biol. Chem. 278 2003 39697 39705
61. D. Faulhammer, B. Eschgfaller, S. Stark, P. Burgstaller, W. Englberger, and J. Erfurth Biostable aptamers with antagonistic properties to the neuropeptide nociceptin/orphanin FQ RNA 10 2004 516 527
62. A. Vater, F. Jarosch, K. Buchner, and S. Klussmann Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: tailored-SELEX Nucleic Acids Res. 31 2003 e130
63. M. Khati, M. Schuman, J. Ibrahim, Q. Sattentau, S. Gordon, and W. James Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2′F-RNA aptamers J. Virol. 77 2003 12692 12698
64. S.H. Jeon, B. Kayhan, T. Ben-Yedidia, and R. Arnon A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral haemagglutinin J. Biol. Chem. 279 2004 48410 48419
65. M.M. Masud, M. Kuwahara, H. Ozaki, and H. Sawai Sialyllactose-binding modified DNA aptamer bearing additional functionality by SELEX Bioorg. Med. Chem. 12 2004 1111 1120
66. S.E. Lupold, B.J. Hicke, Y. Lin, and D.S. Coffey Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen Cancer Res. 62 2002 4029 4033
67. C.H. Chen, G.A. Chernis, V.Q. Hoang, and R. Landgraf Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3 Proc. Natl. Acad. Sci. USA 100 2003 9226 9231
68. T. Mori, A. Oguro, T. Ohtsu, and Y. Nakamura RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family Nucleic Acids Res. 32 2004 6120 6128
69. S. Santulli-Marotto, S.K. Nair, C. Rusconi, B. Sullenger, and E. Gilboa Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity Cancer Res. 63 2003 7483 7489
70. K.N. Morris, K.B. Jensen, C.M. Julin, M. Weil, and L. Gold High affinity ligands from in vitro selection: complex targets Proc. Natl. Acad. Sci. USA 95 1998 2902 2907
71. J. Wang, H. Jiang, and F. Liu In vitro selection of novel RNA ligands that bind human cytomegalovirus and block viral infection RNA 6 2000 571 583
72. M. Homann, and H.U. Goringer Combinatorial selection of high affinity RNA ligands to live African trypanosomes Nucleic Acids Res. 27 1999 2006 2014
73. M. Homann, and H.U. Goringer Uptake and intracellular transport of RNA aptamers in African trypanosomes suggest therapeutic "piggy-back" approach Bioorg. Med. Chem. 9 2001 2571 2580
74. M. Blank, T. Weinschenk, M. Priemer, and H. Schluesener Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. selective targeting of endothelial regulatory protein pigpen J. Biol. Chem. 276 2001 16464 16468
75. D.A. Daniels, H. Chen, B.J. Hicke, K.M. Swiderek, and L. Gold A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment Proc. Natl. Acad. Sci. USA 100 2003 15416 15421
76. B.J. Hicke, C. Marion, Y.F. Chang, T. Gould, C.K. Lynott, and D. Parma Tenascin-C aptamers are generated using tumor cells and purified protein J. Biol. Chem. 276 2001 48644 48654
77. L. Cerchia, F. Duconǵ, C. Pestourie, J. Boulay, Y. Aissouni, and K. Gombert Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase Public Library Sci. 2005 e123
78. K. Thiel Oligo oligarchy - the surprisingly small world of aptamers Nat. Biotechnol. 22 2004 649 651
79. B.J. Hicke, and A.W. Stephens Escort aptamers: a delivery service for diagnosis and therapy J. Clin. Invest. 106 2000 923 928
80. J. Charlton, J. Sennello, and D. Smith In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase Chem. Biol. 4 1997 809 816
81. B. Kuhnast, F. Dolle, S. Terrazzino, B. Rousseau, C. Loc'h, and F. Vaufrey General method to label antisense oligonucleotides with radioactive halogens for pharmacological and imaging studies Bioconjug. Chem. 11 2000 627 636
82. B. Tavitian, S. Terrazzino, B. Kuhnast, S. Marzabal, O. Stettler, and F. Dolle In vivo imaging of oligonucleotides with positron emission tomography Nat. Med. 4 1998 467 471
83. 18F- labelled Spiegelmers: a new class of oligonucleotidic radiopharmaceuticals Eur. J. Nucl. Med. Mol. Imaging 32 2005 (in press) 470-477
84. S.M. Knudsen, and A.D. Ellington Ribozyme deja vu Nat. Struct. Mol. Biol. 11 2004 301 303
85. J. Tang, and R.R. Breaker Rational design of allosteric ribozymes Chem. Biol. 4 1997 453 459
86. S. Brantl Bacterial gene regulation: from transcription attenuation to riboswitches and ribozymes Trends Microbiol. 12 2004 473 475
87. M. Mandal, M. Lee, J.E. Barrick, Z. Weinberg, G.M. Emilsson, and W.L. Ruzzo A glycine-dependent riboswitch that uses cooperative binding to control gene expression Science 306 2004 275 279
88. V. Ambros The functions of animal microRNAs Nature 431 2004 350 355
89. B.C. Yoo, F. Kragler, E. Varkonyi-Gasic, V. Haywood, S. Archer-Evans, and Y.M. Lee A systemic small RNA signaling system in plants Plant Cell 16 2004 1979 2000
90. L.S. Green, D. Jellinek, C. Bell, L.A. Beebe, B.D. Feistner, and S.C. Gill Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor Chem. Biol. 2 1995 683 695
91. K.S. Schmidt, S. Borkowski, J. Kurreck, A.W. Stephens, R. Bald, and M. Hecht Application of locked nucleic acids to improve aptamer in vivo stability and targeting function Nucleic Acids Res. 32 2004 5757 5765
92. F. Darfeuille, J.B. Hansen, H. Orum, C. Di Primo, and J.J. Toulme LNA/DNA chimeric oligomers mimic RNA aptamers targeted to the TAR RNA element of HIV-1 Nucleic Acids Res. 32 2004 3101 3107
93. S. Leva, A. Lichte, J. Burmeister, P. Muhn, B. Jahnke, and D. Fesser GnRH binding RNA and DNA Spiegelmers: a novel approach toward GnRH antagonism Chem. Biol. 9 2002 351 359
94. W.G. Purschke, F. Radtke, F. Kleinjung, and S. Klussmann A DNA Spiegelmer to staphylococcal enterotoxin B Nucleic Acids Res. 31 2003 3027 3032
95. L.S. Green, D. Jellinek, R. Jenison, A. Ostman, C.H. Heldin, and N. Janjic Inhibitory DNA ligands to platelet-derived growth factor B-chain Biochemistry 35 1996 14413 14424
96. M.C. Willis, B.D. Collins, T. Zhang, L.S. Green, D.P. Sebesta, and C. Bell Liposome-anchored vascular endothelial growth factor aptamers Bioconjug. Chem. 9 1998 573 582
97. K.G. Carrasquillo, J.A. Ricker, I.K. Rigas, J.W. Miller, E.S. Gragoudas, and A.P. Adamis Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres Invest. Ophthalmol. Vis. Sci. 44 2003 290 299
98. O.C. Farokhzad, S. Jon, A. Khademhosseini, T.N. Tran, D.A. Lavan, and R. Langer Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells Cancer Res. 64 2004 7668 7672
99. A. DeAnda Jr., S.E. Coutre, M.R. Moon, C.M. Vial, L.C. Griffin, and V.S. Law Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass Ann. Thorac. Surg. 58 1994 344 350
100. L. Reyderman, and S. Stavchansky Pharmacokinetics and biodistribution of a nucleotide-based thrombin inhibitor in rats Pharm. Res. 15 1998 904 910
101. H. Dougan, D.M. Lyster, C.V. Vo, A. Stafford, J.I. Weitz, and J.B. Hobbs Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood Nucl. Med. Biol. 27 2000 289 297
102. C. Bell, E. Lynam, D.J. Landfair, N. Janjic, and M.E. Wiles Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro In Vitro Cell. Dev. Biol. Anim. 35 1999 533 542
103. D.W. Drolet, J. Nelson, C.E. Tucker, P.M. Zack, K. Nixon, and R. Bolin Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys Pharm. Res. 17 2000 1503 1510
104. C.E. Tucker, L.S. Chen, M.B. Judkins, J.A. Farmer, S.C. Gill, and D.W. Drolet Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys J. Chromatogr. B Biomed. Sci. Appl. 732 1999 203 212
105. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration Retina 22 2002 143 152
106. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results Ophthalmology 110 2003 979 986
107. T. Ostendorf, U. Kunter, H.J. Grone, F. Bahlmann, H. Kawachi, and F. Shimizu Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis J. Am. Soc. Nephrol. 12 2001 909 918
108. T. Ostendorf, U. Kunter, C. van Roeyen, S. Dooley, N. Janjic, and J. Ruckman The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-beta system J. Am. Soc. Nephrol. 13 2002 658 667
109. R.R. White, S. Shan, C.P. Rusconi, G. Shetty, M.W. Dewhirst, and C.D. Kontos Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2 Proc. Natl. Acad. Sci. USA 100 2003 5028 5033